

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Stephen D. HURST, et al.

Application No.: Not yet known.

Filed: Herewith

For: CYTOKINE USES;
COMPOSITIONS; METHODS

Examiner: Not yet known.


Art Unit: Not yet known.

"Express Mailing" mailing label number EL 982 851 029 US

Date of Deposit: November 10, 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

by:


Tom Brody

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

USE OF PRIOR SEQUENCE SUBMISSION UNDER 37 CFR §1.821(e)

Honorable Sir:

The attached copy of the Sequence Submission is for the patent application submitted herewith. The computer readable form in this application is equivalent to that filed on April 17, 2001 in the parent application USSN 09/836,385. In accordance with 37 CFR §1.821(e), please use the computer readable form, submitted on April 17, 2001, as the computer readable form in the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application.

The attached copy of the Sequence Submission was originally submitted to the Patent Office in the parent application, USSN 09/836,385, for incorporation into the specification, on April 17, 2001.

Respectfully submitted,

Date: November 10, 2003

By: Tom Brody
Tom Brody
Patent Agent
Registration No.: 46,433

Customer No. 028008

DNAX Research, Inc.
901 California Avenue
Palo Alto, CA 94304-1104
Telephone: (650) 496-6400
Facsimile No.: (650) 496-1200

Enclosed: Copy of Sequence Listing filed April 17, 2001 (4 pages).